Scarica l'app Stockscreener
8.71
1.52%
0.13
Surrozen Inc Borsa (SRZN) Ultime notizie
Surrozen (NASDAQ:SRZN) Shares Up 2.4% - Defense World
(SRZN) Investment Analysis - Stock Traders Daily
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60% - MSN
How to Take Advantage of moves in (SRZN) - Stock Traders Daily
Head to Head Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) vs. Surrozen (NASDAQ:SRZN) - Defense World
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation - Simply Wall St
SRZN Stock Earnings: Surrozen Misses EPS for Q2 2024 - InvestorPlace
Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
Surrozen Provides Second Quarter 2024 Financial Results and Business Update - Yahoo Finance
Surrozen (NASDAQ:SRZN) and AIM ImmunoTech (NYSE:AIM) Head-To-Head Comparison - Defense World
Surrozen (NASDAQ:SRZN) Stock Price Up 1.3% - Defense World
(SRZN) Trading Report - Stock Traders Daily
Trading (SRZN) With Integrated Risk Controls - Stock Traders Daily
Surrozen (NASDAQ:SRZN) Stock Price Down 10.4% - Defense World
Surrozen announces director resignation - Investing.com India
Surrozen announces director resignation - Investing.com
Surrozen Announces Tim Kutzkey’s Board Resignation - TipRanks
(SRZN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
SRZNSurrozen, Inc. Latest Stock News & Market Updates - StockTitan
How the (SRZN) price action is used to our Advantage - Stock Traders Daily
Board of Trustees of The Leland Stanford Junior University Has $490000 Stock Holdings in Surrozen, Inc. (NASDAQ ... - Defense World
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique - EIN News
Surrozen Publishes Study in 'eLife' Demonstrating the - GlobeNewswire
Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique ... - StockTitan
Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique ... - Yahoo Finance
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewswire
Surrozen reports positive Phase 1a trial results for liver therapy - Investing.com India
Surrozen reports positive Phase 1a trial results for liver therapy By Investing.com - Investing.com Australia
Surrozen reports positive Phase 1a trial results for liver therapy By Investing.com - Investing.com
Surrozen reports positive Phase 1a trial results for liver therapy By Investing.com - Investing.com UK
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a ... - Investing News Network
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a ... - GlobeNewswire
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and ... - The Bakersfield Californian
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a ... - StockTitan
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan - Investing News Network
(SRZN) On The My Stocks Page - Stock Traders Daily
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - GlobeNewswire
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - Yahoo Finance
New Strong Buy Stocks for April 12th - Yahoo Movies UK
New Strong Buy Stocks for April 12th - Yahoo Movies Canada
Surrozen (NASDAQ:SRZN) Trading Down 5.9% - Defense World
Surrozen (SRZN) Price Target Decreased by 40.00% to 20.66 - MSN
When the Price of (SRZN) Talks, People Listen - Stock Traders Daily
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial ... - GlobeNewswire
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting - GlobeNewswire Inc.
Surrozen presents data demonstrating potentialfor Wnt mimetic technologiesTipRanks.com - TipRanks
Surrozen Provides First Quarter 2024 Financial Results and Business Update - GlobeNewswire
Surrozen Provides First Quarter 2024 Financial Results and Business Update - Yahoo Finance
Surrozen CFO and COO acquires $232966 in stock warrants - Investing.com Nigeria
Surrozen director Tim Kutzkey acquires $3m in company stock By Investing.com - Investing.com Nigeria
Surrozen CFO and COO acquires $232,966 in stock warrants By Investing.com - Investing.com Nigeria
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis - GlobeNewswire Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating ... - Yahoo Finance
Surrozen Highlights SZN-043 Data on Safety and Liver Function - TipRanks
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 - GlobeNewswire Inc.
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Surrozen Promotes Charles Williams to COO with CFO RoleTipRanks.com - TipRanks
HRMY: Are These 3 Biotech Stocks Worth Buying? - StockNews.com
Daily Digest: Why Instacart stock has sweetened; Swinerton ponies up fine - The Business Journals
GMAB: 3 Biotech Stocks to Watch in November - StockNews.com
Surrozen Provides Third Quarter 2023 Financial Results - Yahoo Finance
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer - Business Wire
Surrozen Provides Second Quarter 2023 Financial Results - GlobeNewswire
Novel FZD4-selective WNT surrogate improves stroke outcomes and BBB function in mice - BioWorld Online
Surrozen IncCompany Profile - GlobalData
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates - Yahoo Finance
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
Surrozen To Report Fourth Quarter and Full Year 2022 - GlobeNewswire
Surrozen selects Trial Interactive eClinical Platform from TransPerfect - Clinical Trials Arena
Surrozen Pauses Phase I Trial Following Liver Enzyme Elevations - BioSpace
1.28%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):